A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 01 Jul 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Anagrelide; Interferon alpha; Peginterferon alfa
Indications Essential thrombocythaemia
Focus Therapeutic Use
Acronyms RUXBETA

Most Recent Events

28 Jun 2021 Status changed from active, no longer recruiting to discontinued.
17 Jul 2018 Status changed from recruiting to active, no longer recruiting.
08 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight